



September 2024 Grand Rounds: Assess and Treat Obesity as a Chronic Disease

Credit for this course may not exceed 1 credit when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 202573217

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 202573221

Important Dates for On-Demand Course (Enduring Material)

Date of Release: October 1, 2024

Date of Termination: December 31, 2026

Learning Objectives

1. After participating in the webinar, learners will be able to discuss the appropriate individual therapeutic targets with patients and adapt the choice of the modalities of intervention according to the probability of achieving the targets.
2. After this webinar, learners will be able to perform a diagnostic work-up and staging of obesity not based solely on the presence of an abnormal and/or excessive fat accumulation (anthropometric component), but including a careful analysis of the present and potential effects that dysfunctional and/or excessive fat accumulation may have on health (clinical component).

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity - including faculty, planners, reviewers or others - are required to disclose all financial relationships with ineligible entities¹ (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate financial relationships. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. In the list below, the nature of the relationship and company are followed by the industry of that company.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker). In the case of this webinar, the chair was also a planner, so disclosures have been included in this document.

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

Panelists:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that “The content and/or presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased.”

Speaker Disclosures:

Luca Busetto, MD, PhD	Advisor relationship with Boehringer Ingelheim (Pharmaceuticals), Bruno Farmaceutici (Pharmaceuticals), Eli Lilly (Pharmaceuticals), Novo Nordisk (Pharmaceuticals), and Pfizer (Pharmaceuticals). Speaker relationship with PronoKal (Supplement) and Rhythm (Pharmaceuticals).
-----------------------	---

Planner Disclosures:

Monica Agarwal, MD	No Relevant Financial Relationships
Johnny Figueroa, PhD	No Relevant Financial Relationships
Leslie Golden, MD, MPH	No Relevant Financial Relationships
Valentina Ivezaj, PhD	No Relevant Financial Relationships
Aaron Kelly, PhD	No Relevant Financial Relationships
Robert Kushner, MD	Advisor Relationship with Novo Nordisk (Pharmaceuticals), WW (Medical Food), and Eli Lilly (Pharmaceuticals) Consultant relationship with Altimmune (Pharmaceuticals), Pfizer Inc. (Pharmaceuticals), and Boehringer Ingelheim (Pharmaceuticals)
Magdalena Pasarica, MD, PhD	No Relevant Financial Relationships
Jonathan Purnell, MD	Consultation Relationship with Novo Nordisk (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), and Luciole (Pharmaceuticals)
Amanda Velazquez, MD	Advisor relationship with WW (Medical Food) Consultation Relationship with Novo Nordisk (Pharmaceuticals)
Denise Wilfley, PhD	No Relevant Financial Relationships

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH. A new framework for the diagnosis, staging and management of obesity in adults. *Nat Med*. 2024 Jul 5. doi: 10.1038/s41591-024-03095-3. PMID: 38969880.
2. Busetto L, Sbraccia P, Vettor R. Obesity management: at the forefront against disease stigma and therapeutic inertia. *Eat Weight Disord*. 2022 Mar;27(2):761-768. doi: 10.1007/s40519-021-01217-1. Epub 2021 May 29. PMID: 34052990; PMCID: PMC8933346.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated August 26, 2024